Sanofi Completely Liquid Type IV Meningococcal Vaccine Menquad P Expands Indications...Can be inoculated from 6 weeks of age
Sep 04, 2025
|
With the expansion of the indication, MenquadP will become the first tetravalent meningococcal polysaccharide-protein conjugate vaccine in Korea that can be inoculated even for six-week-old infants, and will be able to provide options to prevent invasive meningococcal infections in a wider age group.
Menquadpie contains 10 μg of antigen for each of the four meningococcal serotypes A, C, W, and Y, and is a fully liquid formulation that can be administered immediately without separate dilution or mixing, increasing ease of use. In addition, tetanus toxoid (TT) is used as an immune response-inducing protein to induce a strong T-cell-based immune response.
With the expansion of the indications, Menquadpie will provide a flexible vaccination schedule for each age from 6 weeks to 55 years of age. A total of four doses are available for infants under six months of age from six weeks of age, the initial three doses are administered at least eight weeks apart, and the fourth dose is recommended at least six months after the third dose and more than 12 months of age. Infants from 6 months to less than 24 months of age without a history of meningococcal vaccination should receive a total of two doses at least 3 months apart, with a second dose to take place after 12 months of age. In addition, the prevention effect can be expected with only one dose in the age group between 2 and 55 years old.
Park Hee-kyung, CEO of Sanofi's Vaccine Division, said "We are very meaningful that this expansion of Menquadpi's domestic indications laid the foundation for protecting infants and toddlers from invasive meningococcal infection from the early 6 weeks of age.""Meningococcal infection is an infectious disease that progresses rapidly in infants and children and can have fatal consequences, and prevention is of great importance." In the future, Sanofi will continue to work closely with health authorities to ensure safety from meningococcal infections in various age groups and continue to strive to strengthen prevention strategies." We will do our best to ensure that Menquadpie is established as a reliable preventive option for various age groups in an environment where the risk of infection can increase through group life such as travel, military enlistment, and dormitory life," he added.
On the other hand, meningococcal infections are acute infections caused by bacteria called Neisseria meningitidis, a severe disease that mainly causes meningitis and sepsis. The condition is fatal enough to be life-threatening even within hours due to sudden progression of symptoms, and initially begins with cold-like symptoms such as fever, loss of appetite, and nausea, but delays in treatment lead to a death rate of up to 50%. Accordingly, health authorities in each country, including the World Health Organization (WHO), recommend vaccination as the most effective prevention method, and the importance of vaccination is emphasized not only for high-risk groups, but also for group workers and overseas travelers. Considering the possibility of transmission of meningococcal meningitis, the Korea Centers for Disease Control and Prevention has designated it as a second-class legal infectious disease that requires isolation in case of an outbreak or epidemic and must be reported within 24 hours.
This article was translated by Naver AI translator.
